Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Over-the-scope hemoclip prevails for upper GI bleeding

Key clinical point: Use of a large over-the-scope hemoclip for initial endoscopic treatment of severe nonvariceal upper GI bleeding resulted in a markedly lower 30-day rebleeding rate.

Major finding: The number-needed-to-treat with an over-the-scope large hemoclip rather than standard hemostasis for severe nonvariceal upper GI bleeding to avoid one additional case of rebleeding within 30 days was 4.2.

Study details: This was a two-center, prospective, randomized, double-blind clinical trial of 49 patients undergoing initial treatment for severe nonvariceal upper GI bleeding.

Disclosures: The presenter reported having no financial conflicts of interest.

Citation:

Jensen DM. ACG 2019, Abstract 8.